Recent Updates
Recently added Catalysts
IVVD Negative Sentiment Score: 20/100

INVIVYD SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI

Key Takeaway: An alert by Kahn Swick & Foti, LLC has been issued to remind investors of their legal rights regarding a class action lawsuit against Invivyd, Inc. This lawsuit is in response to the company allegedly failing to disclose critical information about its COVID-19 treatment, ADG20. The shares experienced a significant drop of nearly 80% following the revelation that ADG20 was far less effective against the Omicron variant than previously claimed. Investors who lost over $100,000 during a specific class period are encouraged to act before the April 3, 2023 deadline to file lead plaintiff applications.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors face losses over $100,000 due to class action lawsuit against Invivyd.
  • Company accused of failing to disclose material information during Class Period.
  • Stock price dropped nearly 80% after negative test results for its lead product.

Full Press Release Details

NEW ORLEANS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 3, 2023 to file lead plaintiff applications in a securities class action lawsuit against Invivyd, Inc. (the “Company”) (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. (“Adagio”) (NasdaqGM: ADGI), if they purchased the Company’s shares between November 29, 2021 and December 14, 2021, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Massachusetts.
If you purchased shares of Invivyd and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgm-ivvd/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 3, 2023.
Invivyd and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 14, 2021, the Company (then named Adagio) disclosed that in vitro test results for ADG20, its lead product candidate against the COVID-19 Omicron variant, revealed that it was 300 times less effective at neutralizing Omicron than it was against the other variants, despite assuring investors of the efficacy against Omicron only a few weeks prior.
On this news, shares of Adagio plummeted nearly 80%, from $34.26 per share on December 13, 2021, to $7.26 per share when the market closed on December 14, 2021.
The case is Brill v. Invivyd, Inc., No. 23-cv-10254.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 3200
New Orleans, LA 70163

Tags

Frequently Asked Questions

What is the deadline for lead plaintiff applications in the lawsuit?

The deadline to file lead plaintiff applications is April 3, 2023.

What was the main issue in the Invivyd securities lawsuit?

The lawsuit alleges Invivyd failed to disclose crucial information, breaching securities laws.

When did Adagio disclose the effectiveness of ADG20?

Adagio revealed the test results for ADG20 on December 14, 2021.

How much did Adagio's shares drop after the disclosure?

Adagio shares fell nearly 80%, from $34.26 to $7.26 per share.

Who can investors contact regarding their legal rights?

Investors can contact Lewis Kahn at KSF for information without obligation.

Last updated: Feb 22, 2023